Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kyntra Bio (KYNB) Finished Goods (2018 - 2024)

Historic Finished Goods for Kyntra Bio (KYNB) over the last 7 years, with Q3 2024 value amounting to $5.2 million.

  • Kyntra Bio's Finished Goods rose 1307.74% to $5.2 million in Q3 2024 from the same period last year, while for Sep 2024 it was $5.2 million, marking a year-over-year increase of 1307.74%. This contributed to the annual value of $5.6 million for FY2023, which is 7465.54% up from last year.
  • As of Q3 2024, Kyntra Bio's Finished Goods stood at $5.2 million, which was up 1307.74% from $4.9 million recorded in Q2 2024.
  • Over the past 5 years, Kyntra Bio's Finished Goods peaked at $8.2 million during Q4 2021, and registered a low of $3.2 million during Q4 2022.
  • For the 5-year period, Kyntra Bio's Finished Goods averaged around $5.6 million, with its median value being $5.2 million (2022).
  • In the last 5 years, Kyntra Bio's Finished Goods surged by 287986.58% in 2020 and then tumbled by 6084.88% in 2022.
  • Over the past 5 years, Kyntra Bio's Finished Goods (Quarter) stood at $6.1 million in 2020, then surged by 33.37% to $8.2 million in 2021, then crashed by 60.85% to $3.2 million in 2022, then soared by 74.66% to $5.6 million in 2023, then fell by 6.48% to $5.2 million in 2024.
  • Its last three reported values are $5.2 million in Q3 2024, $4.9 million for Q2 2024, and $5.7 million during Q1 2024.